BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces that five companies are to receive additional financial support through its Venture House program, created to further support former Venture Lab companies through their next phase of growth. Read more…
Turku, Finland – March 15, 2023 – DelSiTech Ltd, a Finnish drug delivery and drug development company, today announces that it has been awarded a grant from the Bill & Melinda Gates Foundation to develop long-acting injectable formulations ensuring the slow release of human immunodeficiency virus (HIV) vaccine. This funding marks the third grant awarded from the Bill […]
First-in-class SK channel inhibition proof of mechanism achieved First new approach to treating Atrial Fibrillation for 20 years Copenhagen, Denmark – Acesion Pharma (“Acesion”), the biotech pioneering first-in-class novel therapies for Atrial Fibrillation (“AF”), the most common cardiac arrhythmia, today announced positive data from its Phase 2 trial of AP30663, a first-in-class SK ion channel […]
BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces that it has accepted a new project into its Bio Studio program to develop an engineered mycoprotein meat alternative. Called ”Yummowia”, the project is a spin-out from the Technical University of Denmark and will be led by Professor Irina […]
BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces that ten new companies have entered its Venture Lab acceleration program for early-stage start-ups. The cohort strategically aligns with BII’s focus on developing ground-breaking scientific initiatives to benefit human and planetary health. Read more…
